Cargando…

cMyBPC phosphorylation modulates the effect of omecamtiv mecarbil on myocardial force generation

Omecamtiv mecarbil (OM), a direct myosin motor activator, is currently being tested as a therapeutic replacement for conventional inotropes in heart failure (HF) patients. It is known that HF patients exhibit dysregulated β-adrenergic signaling and decreased cardiac myosin-binding protein C (cMyBPC)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mamidi, Ranganath, Holmes, Joshua B., Doh, Chang Yoon, Dominic, Katherine L., Madugula, Nikhil, Stelzer, Julian E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Rockefeller University Press 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7953254/ https://www.ncbi.nlm.nih.gov/pubmed/33688929 http://dx.doi.org/10.1085/jgp.202012816

Ejemplares similares

AAV9 gene transfer of cMyBPC N-terminal domains ameliorates cardiomyopathy in cMyBPC-deficient mice
por: Li, Jiayang, et al.
Publicado: (2020)

The contribution of N-terminal truncated cMyBPC to in vivo cardiac function
por: Dominic, Katherine L., et al.
Publicado: (2023)

cMyBPC phosphorylation alters response to heart failure drug
por: Short, Ben
Publicado: (2021)

Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil
por: Planelles-Herrero, Vicente J., et al.
Publicado: (2017)

Allosteric modulation of cardiac myosin dynamics by omecamtiv mecarbil
por: Hashem, Shaima, et al.
Publicado: (2017)

Effects of omecamtiv mecarbil and mavacamten in isolated human atrium
por: Abella, Lina Maria Rayo, et al.
Publicado: (2022)

Cardioprotective Properties of Omecamtiv Mecarbil against Ischemia and Reperfusion Injury
por: Stroethoff, Martin, et al.
Publicado: (2019)

Effect of Varying Degrees of Renal Impairment on the Pharmacokinetics of Omecamtiv Mecarbil
por: Trivedi, Ashit, et al.
Publicado: (2021)

Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil
por: Kaplinsky, Edgardo, et al.
Publicado: (2018)

Omecamtiv mecarbil evokes diastolic dysfunction and leads to periodic electromechanical alternans
por: Fülöp, Gábor Á., et al.
Publicado: (2021)

Effects of omecamtiv mecarbil on failing human ventricular trabeculae and interaction with (−)‐noradrenaline
por: Dashwood, Alexander, et al.
Publicado: (2021)

Orthophosphate increases the efficiency of slow muscle-myosin isoform in the presence of omecamtiv mecarbil
por: Governali, Serena, et al.
Publicado: (2020)

Effects of omecamtiv mecarbil on calcium‐transients and contractility in a translational canine myocyte model
por: Gao, BaoXi, et al.
Publicado: (2020)

Omecamtiv Mecarbil: A Novel Mechanistic and Therapeutic Approach to Chronic Heart Failure Management
por: Patel, Pooja H, et al.
Publicado: (2021)

Effects of omecamtiv mecarbil on the contractile properties of skinned porcine left atrial and ventricular muscles
por: Nakanishi, Tomohiro, et al.
Publicado: (2022)

Pharmacokinetic Drug‐Drug Interaction Study of Omecamtiv Mecarbil With Amiodarone and Digoxin in Healthy Subjects
por: Trivedi, Ashit, et al.
Publicado: (2021)

Safety and efficacy of omecamtiv mecarbil for heart failure: A systematic review and meta-analysis
por: Alqatati, Fadel, et al.
Publicado: (2022)

Altered Left Ventricular Rat Gene Expression Induced by the Myosin Activator Omecamtiv Mecarbil
por: El Oumeiri, Bachar, et al.
Publicado: (2023)

Effects of the cardiac myosin activator Omecamtiv-mecarbil on severe chronic aortic regurgitation in Wistar rats
por: El-Oumeiri, Bachar, et al.
Publicado: (2018)

Positive cardiac inotrope omecamtiv mecarbil activates muscle despite suppressing the myosin working stroke
por: Woody, Michael S., et al.
Publicado: (2018)

Omecamtiv mecarbil lowers the contractile deficit in a mouse model of nebulin-based nemaline myopathy
por: Lindqvist, Johan, et al.
Publicado: (2019)

Omecamtiv mecarbil augments cardiomyocyte contractile activity both at resting and systolic Ca(2+) levels
por: Ráduly, Arnold Péter, et al.
Publicado: (2023)

The myosin activator omecamtiv mecarbil improves wall stress in a rat model of chronic aortic regurgitation
por: El Oumeiri, Bachar, et al.
Publicado: (2021)

Comprehensive in vitro pro‐arrhythmic assays demonstrate that omecamtiv mecarbil has low pro‐arrhythmic risk
por: Qu, Yusheng, et al.
Publicado: (2021)

Omecamtiv mecarbil treatment improves post-resuscitation cardiac function and neurological outcome in a rat model
por: Wu, Shih-Ni, et al.
Publicado: (2022)

Generative adversarial networks for construction of virtual populations of mechanistic models: simulations to study Omecamtiv Mecarbil action
por: Parikh, Jaimit, et al.
Publicado: (2021)

Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial
por: Metra, Marco, et al.
Publicado: (2022)

Characterization of Stimulatory Action on Voltage-Gated Na(+) Currents Caused by Omecamtiv Mecarbil, Known to Be a Myosin Activator
por: Ting, Chih-Yu, et al.
Publicado: (2023)

Opposite diastolic effects of omecamtiv mecarbil versus dobutamine and ivabradine co‐treatment in pigs with acute ischemic heart failure
por: Rønning, Leif, et al.
Publicado: (2018)

Myosin with hypertrophic cardiac mutation R712L has a decreased working stroke which is rescued by omecamtiv mecarbil
por: Snoberger, Aaron, et al.
Publicado: (2021)

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC‐HF baseline characteristics and comparison with contemporary clinical trials
por: Teerlink, John R., et al.
Publicado: (2020)

Effects of Omecamtiv Mecarbil on Symptoms and Health-Related Quality of Life in Patients With Chronic Heart Failure: Results From the COSMIC-HF Study
por: Felker, G. Michael, et al.
Publicado: (2020)

Impact of the Myosin Modulator Mavacamten on Force Generation and Cross‐Bridge Behavior in a Murine Model of Hypercontractility
por: Mamidi, Ranganath, et al.
Publicado: (2018)

Relative bioavailability, food effect, and safety of the single-dose pharmacokinetics of omecamtiv mecarbil following administration of different modified-release formulations in healthy subjects
por: Palaparthy, Rameshraja, et al.
Publicado: (2016)

Cardiac Myosin Binding Protein-C Phosphorylation Modulates Myofilament Length-Dependent Activation
por: Mamidi, Ranganath, et al.
Publicado: (2016)

Cardiac myosin binding protein-C Ser(302) phosphorylation regulates cardiac β-adrenergic reserve
por: Mamidi, Ranganath, et al.
Publicado: (2017)

Evaluation of drug‐drug interaction potential between omecamtiv mecarbil and rosuvastatin, a BCRP substrate, with a clinical study in healthy subjects and using a physiologically‐based pharmacokinetic model
por: Trivedi, Ashit, et al.
Publicado: (2021)

Rational Design of Cyclic Antimicrobial Peptides Based on BPC194 and BPC198
por: Cirac, Anna D., et al.
Publicado: (2017)

Length-dependent changes in contractile dynamics are blunted due to cardiac myosin binding protein-C ablation
por: Mamidi, Ranganath, et al.
Publicado: (2014)

Unofficial Formulary, B.P.C.
Publicado: (1888)

Cannot write session to /tmp/vufind_sessions/sess_f6p90i7em3mo8m5up7n80bfacj